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Abstract 
Context: Common community-acquired infections, such as cytomegalovirus (CMV), may 
contribute to the development of obesity and metabolic dysfunction, but empirical evidence 
is scarce.  
Objective: We examined the associations between CMV, obesity and metabolic 
characteristics in a large, general population-based sample of adults.  
Design and setting: An observational study in community dwelling adults from the general 
population, ‘Understanding Society -- the UK Household Longitudinal Study’. 
Participants: 9,517 men and women (aged 52.4 ± 16.4 yrs; 55.3% female).  
Measures: CMV infection was measured using Immunoglobulin G (IgG) from serum. Obesity 
was defined as body mass index ≥30 kg/m2. Based on blood pressure, HDL-cholesterol, 
triglycerides, glycated haemoglobin A1c, and C-reactive protein, participants were classified 
as ‘healthy’ (0 or 1 metabolic abnormality) or ‘unhealthy’ (≥2 metabolic abnormalities).  
Results: A positive CMV test was recorded in 47.5% of the sample. There was no association 
between CMV and obesity. Of the individual metabolic risk factors, CMV was positively 
associated with glycated haemoglobin and HDL-cholesterol. In combination, only ‘unhealthy 
non-obese’ participants had modestly increased odds of CMV (odds ratio compared to 
healthy normal-weight = 1.12, 95% confidence interval 1.00 – 1.26) after adjusting for a 
range of variables. CMV was associated with an increased prevalence of cardiovascular 
diseases (odds ratio=1.67; 1.07 – 2.60) independently of obesity, metabolic risk factors, and 
other covariates. 
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Conclusion: Our findings suggest a weak but statistically significant association between 
CMV and metabolic dysfunction in non-obese adults. This relationship appears to be masked 
in the obese, possibly by the effects of excess adiposity on metabolism. 
Key words: cytomegalovirus; epidemiology; infection; obesity 
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Cytomegalovirus (CMV) is one of the most well-characterised infections in humans.  This 1 
infection is typically acquired in childhood and is lifelong.  Although CMV rarely causes 2 
symptoms, it has been linked to adverse metabolic characteristics, including obesity1-4 and 3 
factors that accompany this condition, such as impaired glucose control and dyslipidaemia.5-4 
12 These associations are biologically plausible because infection provokes immune 5 
responses, such as the release of inflammatory cytokines that have been linked to the 6 
etiology of metabolic disorders including diabetes.13 Infection with CMV might also 7 
contribute to features of immune-senescence, such as the accumulation of differentiated 8 
cytotoxic T cells. Some evidence suggests that the accumulation of these cells could drive an 9 
unfavourable metabolic profile.14 In addition, it has been postulated that excess adipose 10 
tissue may lead to susceptibility to infections, such as CMV,2,4  through influencing a variety 11 
of immune mediators. However, the adverse effects of excess adiposity on metabolism 12 
might also mask any association between CMV and metabolic parameters. 13 
 14 
Existing data on obesity, metabolic dysfunction and acquired infections is generally sparse.  15 
Most studies have suffered from methodological weaknesses such as small sample sizes 16 
(n<150),5,7-8 case-control rather than prospective designs,5,7-8,11 and inadequate adjustment 17 
for sociodemographic factors. To the best of our knowledge, no large-scale studies to date 18 
have simultaneously examined the associations of CMV with both obesity and metabolic 19 
health, controlling for potential confounding factors, such as poor lifestyle and social 20 
disadvantage,12,15 to evaluate the strength of these associations in the general population 21 
and to separate the possible underlying mechanisms. These associations may have 22 
important clinical implications as CMV infections, although common, are not routinely 23 
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subject to screening and treatment is considered only in the rare event the infection is 24 
activated and symptomatic.  25 
 26 
Methods  27 
Understanding Society -- the UK Household Longitudinal Study (UKHLS) -- is a large, 28 
longitudinal survey of households in the United Kingdom (England, Scotland, Wales and 29 
Northern Ireland). In 2010-2012, participants completed a face-to-face interview and nurse 30 
health assessments were conducted approximately five months following completion of the 31 
survey interview.16 In brief, in the general population sample there was a 58.6% response 32 
for the nurse assessment component and full blood samples were successfully collected in 33 
10,175 participants. Participants gave full informed written consent to participate in the 34 
study and ethical approval was obtained from the Ethics Committee of the University of 35 
Essex (main survey) and National Research Ethics Service Oxfordshire REC A (nurse health 36 
assessment). 37 
Nurse health assessment 38 
Nurses collected anthropometric data (weight, height, waist circumference), blood pressure 39 
(BP), and non-fasting blood samples using standard protocols. Body weight was measured 40 
using Tanita BF 522 scales without shoes and in light clothing, and height was measured 41 
using a Stadiometer with the Frankfort plane in the horizontal position. Body mass index 42 
(BMI) was calculated as weight (kilograms)/height (meters) squared. Waist circumference 43 
was recorded twice using measuring tape mid-way between the iliac crest and lower rib. An 44 
average of the first two measurements was used provided these differed by no more than 45 
6 
 
3cm; otherwise a third reading was taken and the two closest results utilised. Systolic and 46 
diastolic BP was measured with an Omron HEM-907 BP monitor three times in the sitting 47 
position after 5-minute rest between each reading. The initial reading was discarded and an 48 
average of the second and third BP recordings was used for the present analyses. All 49 
respondents were eligible to give blood except pregnant women, individuals who 50 
volunteered that they are HIV positive or had hepatitis B or C, persons with clotting or 51 
bleeding disorder such as haemophilia, or those with a self-declared low platelet count.  52 
Additionally, people who had ever had a fit, or those taking anti-clotting medication (e.g., 53 
warfarin) were also excluded. Blood samples were analyzed for C-reactive protein (CRP), 54 
high density lipoprotein (HDL) cholesterol, triglycerides, and glycated haemoglobin (HbA1c). 55 
Detailed information on the technicalities of the blood analysis have been described 56 
elsewhere.17 57 
Measurement of Cytomegalovirus (CMV) antibodies 58 
Immunoglobulin G (IgG) and IgM were measured from serum samples with an 59 
electrochemiluminsecent immunoassay (Roche E170 analyser). Inter- and intra-assay 60 
coefficients of variation were acceptable, less than 4%.  A positive CMV IgG result indicates a 61 
CMV infection at some point in time, while a negative CMV IgG indicates that the participant 62 
has never been exposed to, or been infected with, CMV. A positive Immunoglobulin M (IgM) 63 
indicates a recent or current infection. Indeterminate CMV occurs during current or acute 64 
infection or may be due to non-specific binding. For those people who had a positive IgM 65 
test or whose result was indeterminate, an additional test was performed to confirm recent 66 
CMV infection. This confirmatory assay was an avidity test on the Mini VIDAS immunoassay 67 
analyser.  68 
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Covariables 69 
Health-related questions included cigarette smoking (current; previous ; non-smoker), the 70 
frequency of participation in sports and exercise (more than three times per week; 1 – 3 71 
times per week; once per month or less; never), and the frequency of alcohol intake (at least 72 
5-6/week; 1-4/week; monthy; rarely /never). Participants were also asked to state their 73 
highest educational attainment (Degree; A-level/GCSE; other; none) and to rate their health 74 
(excellent; very good; good; fair; poor). 75 
Statistical analyses 76 
Body mass index was categorised into four groups (normal: from 18.5 to <25 kg/m2 ; 77 
overweight: from 25 to <30 kg/m2 ; obese I: from 30 to <35kg/m2 ; obese II and more severe 78 
forms: ≥ 35 kg/m2).  Based on existing criteria18 unhealthy metabolic status was defined as 79 
having two or more of the following metabolic risk factors: high BP (systolic/diastolic BP 80 
≥130/85 mmHg, or hypertension diagnosis, or use of anti-hypertensive medication), 81 
impaired glycaemic control (HbA1c > 6.0% [42.1 mmol/mol] or doctor’s diagnosed diabetes), 82 
systemic inflammation (CRP ≥ 3mg/l), low HDL cholesterol (<1.03 mmol/l in men and <1.30 83 
mmol/l in women), and high triglycerides (≥ 1.7 mmol/l). Participants were then categorized 84 
into four groups:  ‘healthy non-obese’; ‘unhealthy non-obese’; ‘healthy obese ’; and 85 
‘unhealthy obese’. 86 
We calculated odds ratios (OR) and 95% confidence intervals (CI) for the odds of CMV in 87 
relation to obesity, metabolic status and their combination. We tested for sex interactions, 88 
but as none were present, men and women were pooled in the same analysis. Initially, we 89 
adjusted our effect estimates for sex and age (model 1). We further adjusted the models for 90 
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education, sports and exercise participation, self-rated health, smoking, and alcohol (model 91 
2). Analyses were conducted using SPSS version 22. 92 
 93 
Results  94 
The analytic sample comprised 9,517 participants (aged 52.4 ± 16.4 yrs; 55.3% female). A 95 
positive CMV test was apparent in 47.5% of the sample. Participants testing positive for 96 
CMV tended to be older, female, smokers, have no educational qualifications, and poorer 97 
self-rated health (Table 1).  In logistic regression models mutually adjusted for all variables, 98 
per year increase in age (OR; 95% confidence interval: 1.02, 1.01 – 1.03), being female (1.26; 99 
1.16 – 1.38), a smoker (1.21; 1.07 – 1.37), and no qualifications (1.72; 1.46 – 2.02) remained 100 
associated with CMV positive status. 101 
There was no association between BMI and CMV (Table 2), nor did we observe any 102 
association when using waist circumference as a measure of central obesity (OR per unit 103 
increase = 1.00; 0.99 – 1.01, P=0.94).  Metabolic health was associated with the status of 104 
CMV in models adjusted for age and sex, although after further adjustments the association 105 
was attenuated to the null (Table 2). In analyses that combined obesity and metabolic 106 
health, participants defined as “unhealthy non-obese” had increased odds of being CMV 107 
positive (Table 2). In further analyses to examine associations between individual metabolic 108 
risk factors and CMV we observed significant associations for HbA1C and HDL-cholesterol 109 
(Table 3). 110 
We further examined these associations in relation to a clinically meaningful outcome; 105 111 
self-reported physician-diagnosed cases of cardiovascular diseases (CVD) (including 112 
congestive heart failure, angina/ myocardial infarction/coronary heart disease, and stroke) 113 
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were reported. In analyses (Table 4) in which we adjust our effect estimates for covariates, 114 
CMV was associated with higher odds of CVD (OR = 1.67, 95% CI, 1.07 – 2.60) independently 115 
of obesity and metabolic risk factors.  116 
 117 
Discussion  118 
Our main finding was an association between CMV and the individual metabolic risk factors 119 
of high glycated haemoglobin and low HDL-cholesterol.  However, only metabolically 120 
‘unhealthy non-obese’ participants had an increased prevalence of the acquired infection. In 121 
contrast, CMV was not associated with metabolic health in obese participants and there was 122 
no association between obesity and CMV. In further analyses using a clinical endpoint, CMV 123 
was associated with CVD independently of obesity and metabolic risk factors. 124 
 125 
Existing data on metabolic health and acquired infections is generally sparse.  Most studies 126 
have suffered from methodological weaknesses such as small sample sizes (n<150),5,7-8 case-127 
control rather than prospective designs,5,7-8,11 and inadequate adjustment for 128 
sociodemographic factors. With over 9000 participants, our study is, to the best of our 129 
knowledge, the largest population-based study on CMV in relation to a range of metabolic 130 
factors and obesity. 131 
 132 
Obesity is thought to influence the immune response that has been hypothesised to 133 
increase susceptibility to infections.2,4 However, the most plausible interpretation of our 134 
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findings is that the accumulation of viral load and associated immune activation is driving an 135 
unfavourable metabolic profile among non-obese. Obesity often precedes metabolic 136 
dysfunction,19 thus in obese participants is likely to be the strongest driver of metabolic risk 137 
and might explain why the ‘unhealthy obese’ were seemingly not at elevated risk of CMV 138 
infection in contrast to their non-obese counterparts.   139 
 140 
Associations between CMV and metabolic health were attenuated after adjustment for 141 
social and lifestyle factors, suggesting these relationships could be part of a causal pathway 142 
starting from social determinants of health. This is consistent with findings from a previous 143 
population sample of US adults demonstrating that the association between CMV and 144 
diabetes was attenuated to the null in models accounting for social and lifestyle factors.12 145 
CMV was, however, associated with CVD independently of covariates; this is consistent with 146 
prior evidence.20 CMV is known to increase experimental atherosclerosis and to modulate 147 
vascular-wall activity,21,22 thus the association is likely to be independent of adiposity and 148 
metabolic dysfunction. 149 
 150 
Infection causes immune responses, such as the release of inflammatory cytokines that have 151 
been linked to the etiology of metabolic disorders including diabetes.13 Interestingly, we 152 
found no association between C-reactive protein and CMV, but the link with metabolic 153 
health was driven by HDL-cholesterol and HbA1C. This suggests mechanisms other than 154 
inflammatory response related to innate immunity may primarily drive the association 155 
between CMV and metabolic dysfunction. Recent evidence has shown the accumulation of 156 
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differentiated cytotoxic T cells in CMV positive participants was associated with HbA1C and 157 
cholesterol,14 suggesting a direct role of the immune cells related to the adaptive immune 158 
system. 159 
 160 
There are several limitations. Firstly this is a cross-sectional study thus we can only 161 
speculate on the causality and direction of our findings. Second, our measurement of 162 
pathogen infection was based on seropositivity to IgG antibodies, which reflects prior 163 
infection, but are not sensitive indicators of current infection or the chronicity of prior 164 
infections. Nevertheless, active pathogen infection is unlikely to have influenced our results 165 
as recent infection (measured through positive IgM and confirmatory avidity test) was 166 
apparent in less than 0.5% of the sample and removal of these participants did not influence 167 
the present results (data not shown). Detailed assessments of immune activity were not 168 
possible in the present study. An assessment of T cell pattern in participants with positive or 169 
negative CMV test would provide further hints as to how CMV infection impacts on immune 170 
cell function driving an unfavourable metabolic profile.23 171 
 172 
In summary, we demonstrated no association between obesity and CMV. We identified a 173 
weak but statistically significant association between CMV and metabolic dysfunction in 174 
non-obese adults, but not in their obese counterparts. We speculate that in the non-obese 175 
CMV infection may drive metabolic dysfunction whereas in the obese population excess 176 
adiposity is the main cause of metabolic disturbance. As any associations observed with 177 
metabolic risk factors were weak, our findings do not justify universal screening of CMV to 178 
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prevent diabetes, although there appears to be a stronger association between CMV and 179 
CVD.  180 
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Table 1. Characteristics of the sample according to CMV status (N=9,517) 
Variable CMV positive 
(n=4,524) 
CMV negative 
(n=4,993) 
p-value 
Age (yrs) 56.4 ± 16.0 48.6± 15.8 <0.001 
Sex (%) 
Men  
Women  
 
41.9 
58.1 
 
47.3 
52.7 
<0.001 
Education (%) 
Degree 
A-level/GCSE only 
Other 
No qualification 
 
30.3 
37.7 
13.3 
18.7 
 
38.8 
43.3 
9.4 
8.5 
<0.001 
Smoking (%) 
Never 
Ex-smoker 
Current  
 
37.9 
42.3 
19.7 
 
41.5 
40.0 
18.4 
0.002 
Sports and exercise participation 
(%) 
Never 
Once a month or less 
At least once a week 
More than three times a week  
 
39.7 
27.4 
19.3 
13.6 
 
27.8 
33.7 
22.3 
16.4 
<0.001 
Frequency of Alcohol intake (%) 
At least 5-6 times a week 
Weekly 
Monthly 
Rarely/never  
 
16.4 
41.4 
14.4 
27.8 
 
14.9 
47.8 
15.6 
21.7 
<0.001 
Self–rated health (%) 
Excellent/very good 
Good 
Poor/fair 
 
47.2 
29.9 
23.0 
 
55.1 
28.3 
16.6 
<0.001 
Body mass index (kg/m2) 28.4 ± 5.3 28.0 ± 5.6 <0.001 
Number of metabolic risk factors 1.4 ± 1.2 1.2 ± 1.1 <0.001 
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Table 2: Odds ratios (95% confidence interval) for the relation between obesity, metabolic health 
and history of CMV infection (N=9,517) 
 CASES/N Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Obesity     
Normal (18.5 to <25 kg/m2) 1198/2679 1.0 (Ref) 1.0 (Ref) 
Overweight (25 to < 30 kg/m2) 1871/3893 1.02 (0.92 – 1.13) 1.03 (0.93 – 1.15) 
Obese I (30 to <35 kg/m2) 976/1957 1.08 (0.95 – 1.22) 1.06 (0.93 – 1.20) 
Obese II (≥35 kg/m2) 499/993 1.12 (0.96 – 1.30) 1.04 (0.89 – 1.22) 
p-linear trend  0.10 0.52 
    
Metabolic healthⱡ    
Healthy (0 or 1 risk factor) 2658/5956 1.0 (Ref) 1.0 (Ref) 
Unhealthy (> 1 risk factor) 1891/3584 1.15 (1.05 – 1.25) 1.05 (0.95 – 1.15) 
p-linear trend (continuous score)  0.002 0.41 
    
Metabolic health/ obesity    
Healthy non-obese 2105/4785 1.0 (Ref) 1.0 (Ref) 
Unhealthy non-obese 963/1784 1.22 (1.08 – 1.36) 1.12 (1.00 – 1.26) 
Healthy Obese 546/1151 1.13 (0.99 – 1.29) 1.11 (0.97 – 1.27) 
Unhealthy Obese 927/1797 1.14 (1.02 – 1.28) 1.04 (0.92 – 1.17) 
Model 1: adjusted for age and sex 
Model 2: adjusted for age, sex, education, sports and exercise participation, self rated health, 
smoking, alcohol.  
ⱡdefined from: High blood pressure (clinic BP ≥130/85 mmHg, or hypertension diagnosis, or use of 
anti-hypertensive medication), impaired glycaemic control (HbA1c > 6.0% or doctor’s diagnosed 
diabetes), systemic inflammation (C-reactive protein≥ 3mg/l), low HDL cholesterol (<1.03 mmol/l in 
men and <1.30 mmol/l in women), and high triacylglycerol (≥ 1.7 mmol/l). 
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Table 3: Odds ratios (95% confidence interval) for the relation between individual metabolic risk 
factors and CMV infection  
Risk factor (per standard 
deviation increase)† 
Model 1 (OR, 95% CI) Model 2 (OR, 95% CI) 
HbA1c (8.0 mmol/mol) 1.08 (1.03 – 1.13) 1.01 (1.00 – 1.02) 
HDL-Cholesterol (0.46 mmol/l) 0.91 (0.87 – 0.95) 0.80 (0.71 – 0.90) 
Triglycerides (1.10 mmol/l) 1.03 (0.98 – 1.08) 0.99 (0.94 – 1.03) 
C-Reactive Protein (6.75 mg/l) 1.02 (0.99 – 1.07) 1.00 (0.99 – 1.02) 
Systolic Blood Pressure (16.3 
mmHg) 
0.95 (0.81 – 1.12) 0.94 (0.80 – 1.11) 
†a standard deviation increase denoted after variable 
Model 1: adjusted for age and sex 
Model 2: adjusted for age, sex, education, sports and exercise participation, self rated health, 
smoking, alcohol, BMI, and mutually for other metabolic risk factors. 
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Table 4: Odds ratios (95% confidence interval) for the associations of CMV infection, obesity, 
metabolic health with cardiovascular disease. 
 CVD cases/N Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
CMV infection    
No 30/4976 1.0 (Ref) 1.0 (Ref) 
Yes 75/4541 1.81 (1.17 – 1.80) 1.67 (1.07 – 2.60) 
    
Obesity     
Normal (18.5 to <25 kg/m2) 11/2679 1.0 (Ref) 1.0 (Ref) 
Overweight (25 to < 30 kg/m2) 38/3893 1.60 (0.81 – 3.17) 1.64 (0.82 – 3.28) 
Obese I (30 to <35 kg/m2) 34/1957 2.63 (1.30 – 5.33) 2.35 (1.14 – 4.84) 
Obese II (≥35 kg/m2) 22/993 3.91 (1.81 – 8.42) 2.83 (1.29 – 6.24) 
    
Metabolic health    
Healthy (0 or 1 risk factor) 32/5956 1.0 (Ref) 1.0 (Ref) 
Unhealthy (> 1 risk factor) 73/3584 1.97 (1.26 – 3.08) 1.59 (1.00 – 2.51) 
 
Model 1: adjusted for age, sex, and mutually for CMV, obesity category, or metabolic health. 
Model 2: adjusted for age, sex, education, sports and exercise participation, self rated health, 
smoking, alcohol, and mutually for CMV, obesity, or metabolic health. 
 
